Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study has been completed.
Information provided by (Responsible Party):
The University of Texas Medical Branch, Galveston Identifier:
First received: January 9, 2004
Last updated: February 11, 2013
Last verified: February 2013

RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well arsenic trioxide works in treating patients with locally advanced or metastatic non-small cell lung cancer.

Condition Intervention Phase
Lung Cancer
Drug: arsenic trioxide
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Phase II Protocol Of Arsenic Trioxide (Trisenox) In Subjects With Advanced Non-Small Cell Carcinoma Of The Lung

Resource links provided by NLM:

Further study details as provided by The University of Texas Medical Branch, Galveston:

Estimated Enrollment: 30
Study Start Date: November 2002
Study Completion Date: July 2005
Primary Completion Date: July 2005 (Final data collection date for primary outcome measure)
Detailed Description:



  • Determine the safety and activity of arsenic trioxide in patients with locally advanced or metastatic non-small cell lung cancer.
  • Determine the qualitative and quantitative toxic effects of this drug in these patients.


  • Determine the response, in terms of objective tumor response and response duration, in patients treated with this drug.
  • Determine the patterns of failure and survival in patients treated with this drug.

OUTLINE: This is a pilot study.

Patients receive arsenic trioxide IV over 1-2 hours on days 1-5 of week 1 and on days 1 and 5 of weeks 2-8 (course 1 only). Beginning with course 2 and for all subsequent courses, patients receive arsenic trioxide on days 1 and 5 of weeks 1-8. Treatment repeats every 8 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR) receive 1 additional course of therapy beyond CR. Patients achieving CR due to local consolidative therapy (surgery or radiotherapy) receive 2 additional courses of therapy beyond CR.

Patients are followed for 1 month, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study within 9-18 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed non-small cell lung cancer (NSCLC), meeting criteria for 1 of the following:

    • Locally advanced disease not amenable to radiotherapy or surgery
    • Metastatic disease
  • Received at least 1 course of platinum-based (e.g., cisplatin or carboplatin) chemotherapy
  • No uncontrolled central nervous system (CNS) metastases
  • Ineligible for higher priority treatment protocols



  • 18 and over

Performance status

  • Eastern Cooperative Oncology Group (ECOG) 0-1 OR
  • Zubrod Scale 0-1 OR
  • South West Oncology Group (SWOG) 0-1

Life expectancy

  • At least 12 weeks


  • Absolute neutrophil count greater than 1,500/mm^3
  • Platelet count greater than 100,000/mm^3


  • Bilirubin no greater than 1.5 times normal
  • Serum glutamate oxaloacetate transaminase (SGOT) and Serum glutamate pyruvate transaminase (SGPT) no greater than 3 times normal


  • Creatinine no greater than 2.0 mg/dL
  • Calcium no greater than 12 mg/dL


  • No myocardial infarction within the past 6 months
  • No uncontrolled, clinically significant dysrhythmia
  • Cardiac ejection fraction greater than 50%


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Electrolytes (including magnesium) normal
  • No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
  • No prior or ongoing peripheral neuropathy grade 2 or greater
  • No other medical condition that would preclude study participation


Biologic therapy

  • No concurrent cytokine therapy


  • See Disease Characteristics
  • No more than 2 prior chemotherapy regimens for NSCLC
  • No other concurrent chemotherapy

Endocrine therapy

  • Not specified


  • More than 2 weeks since prior radiotherapy
  • No prior radiotherapy to an indicator lesion unless there is objective evidence of tumor growth in that lesion
  • No concurrent radiotherapy

    • Concurrent palliative or emergent radiotherapy allowed


  • More than 2 weeks since prior surgery


  • At least 4 weeks since prior antineoplastic agents for non-malignant conditions (e.g., methotrexate for rheumatoid arthritis)
  • No concurrent antineoplastic agents for non-malignant conditions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00075426

United States, Texas
University of Texas Medical Branch
Galveston, Texas, United States, 77555-0209
Sponsors and Collaborators
The University of Texas Medical Branch, Galveston
Study Chair: Dennie V. Jones, MD University of Texas
  More Information

Responsible Party: The University of Texas Medical Branch, Galveston Identifier: NCT00075426     History of Changes
Other Study ID Numbers: 02-402
Study First Received: January 9, 2004
Last Updated: February 11, 2013

Keywords provided by The University of Texas Medical Branch, Galveston:
stage IIIA non-small cell lung cancer
stage IIIB non-small cell lung cancer
stage IV non-small cell lung cancer
recurrent non-small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Arsenic trioxide
Antineoplastic Agents processed this record on April 25, 2017